公开(公告)号：US20190040473A1

公开(公告)日：2019-02-07

申请号：US16155220

申请日：2018-10-09

Applicant: GENCURIX INC.

Inventor： Young Kee SHIN ,  Young-Deug KIM ,  En Sel OH ,  Jun Young CHOI ,  Sang Rea CHO

IPC: C12Q1/6886

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

公开(公告)号：US20200071768A1

公开(公告)日：2020-03-05

申请号：US16462655

申请日：2017-11-21

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.The method of the present invention has an effect of being capable of more accurately predicting the future prognosis of metastasis, recurrence, or metastatic recurrence in breast cancer patients, and in particular, has a very excellent ability to predict the prognosis of HER2-type breast cancer, the prognosis of which is very poor, and thus can be usefully used to provide clues for the direction of future treatment of breast cancer.

公开(公告)号：US20190352703A1

公开(公告)日：2019-11-21

申请号：US16304340

申请日：2017-05-25

Applicant: GENCURIX INC.

Inventor： Young Kee SHIN ,  Bohyun BYUN ,  Hyunjeung CHOI ,  Joon Seok CHOI ,  Young Ho MOON ,  Jong Heun LEE ,  Sang Rea CHO ,  Jee Eun KIM ,  Myungsun KIM

IPC: C12Q1/6827 ,  C12Q1/6886 ,  C12Q1/6874 ,  C12Q1/686 ,  C12Q1/6823

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

公开(公告)号：US20160102359A1

公开(公告)日：2016-04-14

申请号：US14886948

申请日：2015-10-19

Applicant: GENCURIX INC.

Inventor： Young Kee SHIN ,  Young-Deug Kim ,  En Sel Oh ,  Jun Young Choi ,  Sang Rea Cho

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2800/52

Abstract: A gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof is disclosed, and more specifically a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3 member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

Abstract translation: 公开了一种用于预测或诊断早期乳腺癌预后的基因及其用途，更具体地，涉及用于预测或诊断乳腺癌预后的遗传标记，包括TRBC1（T细胞受体β常数1），BTN3A2 （雌激素，亚家族3成员A2）或HLA-DPA1（主要组织相容性复合物，II类，DPα1），用于提供预测或诊断乳腺癌患者预后所需的信息。 遗传标记允许预测或诊断乳腺癌患者的预后，因此可以有利地用于为乳腺癌治疗的未来方向提供方向，包括是否需要抗癌治疗的决定。

公开(公告)号：US20180216199A1

公开(公告)日：2018-08-02

申请号：US15938633

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q1/68 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

公开(公告)号：US20180216198A1

公开(公告)日：2018-08-02

申请号：US15938331

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.